Immunovant
Stock Forecast, Prediction & Price Target
Immunovant Financial Estimates
Immunovant Revenue Estimates
Immunovant EBITDA Estimates
Immunovant Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 3/31/2022 | 3/31/2023 | 3/31/2024 | 3/31/2026 | 3/31/2027 | 3/31/2028 | 3/31/2029 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $74.73M Low: $7.74M High: $169.99M avg. 0% | Avg: $271.47M Low: $53.55M High: $581.34M avg. 263.22% | Avg: $731.27M Low: $144.24M High: $1.56B avg. 169.37% | Avg: $1.27B Low: $250.99M High: $2.72B avg. 73.99% |
Net Income
% change YoY
| $-156.73M N/A | $-210.96M -34.60% | $-259.33M -22.93% | Avg: $-339.82M Low: $-378.39M High: $23.47M avg. -31.03% | Avg: $-226.81M Low: $-390.82M High: $29.00M avg. 33.25% | Avg: $59.77M Low: $-2.60M High: $148.48M avg. 126.35% | Avg: $376.02M Low: $-16.38M High: $934.00M avg. 529.03% |
EBITDA
% change YoY
| $-156.03M N/A | $-209.62M -34.34% | $-269.97M -28.78% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$1.43 N/A | -$1.71 -19.58% | -$1.88 -9.94% | Avg: -$2.13 Low: -$2.74 High: $0.17 avg. -13.30% | Avg: -$1.47 Low: -$2.83 High: $0.21 avg. 31.08% | Avg: $0.43 Low: -$0.02 High: $1.08 avg. 129.48% | Avg: $2.72 Low: -$0.12 High: $6.76 avg. 529.03% |
Operating Expenses
% change YoY
| $156.03M N/A | $208.27M 33.48% | $282.70M 35.73% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Immunovant stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 164.40% in 2026-2029.
We have gathered data from 8 analysts. Their low estimate is -378.39M, average is -339.82M and high is 23.47M.
What is Immunovant stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 126.64% in 2026-2029.
We have gathered data from 8 analysts. Their low revenue estimate is $7.74M, average is $74.73M and high is $169.99M.
What is Immunovant stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 169.07% in 2026-2029.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$2.74, average is -$2.13 and high is $0.17.
What is the best performing analyst?
In the last twelve months analysts have been covering Immunovant stock. The most successful analyst is Leland Gershell.